This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	CD3; C-type lectin domain family 12 member A (CLEC12A; CLL1)	<p>Studies in patient samples, mice and cell culture suggest a bispecific antibody against CLL1 and CD3 could help treat AML. In human AML cell lines and patient samples, the bispecific antibody decreased viability with picomolar EC₅₀ values. In a mouse xenograft model of AML, i.v. infusion of the bispecific antibody caused almost complete suppression of tumor growth, whereas saline or a bispecific antibody targeting CD33 and CD3 did not. Next steps could include carrying out IND-enabling safety and efficacy studies for the bispecific antibody.</p> <p>Merus B.V. has MCLA-117, a human bispecific IgG antibody targeting CLL1 and CD3, in preclinical development to treat AML.</p> <p>SciBX 7(33); doi:10.1038/scibx.2014.976 Published online Aug. 28, 2014</p>	Patent and licensing status unavailable	<p>Lu, H. <i>et al. Angew. Chem. Int. Ed.</i>; published online July 23, 2014; doi:10.1002/anie.201405353</p> <p>Contact: Peter G. Schultz, The Scripps Research Institute, La Jolla, Calif. e-mail: schultz@scripps.edu</p> <p>Contact: Chan Hyuk Kim, California Institute for Biomedical Research, La Jolla, Calif. e-mail: chkim@calibr.org</p>